Adaptimmune Therapeutics PLC Annual Net Cash Provided by (Used in) Investing Activities in USD from 2015 to 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.
Summary
Adaptimmune Therapeutics PLC quarterly/annual Net Cash Provided by (Used in) Investing Activities history and growth rate from 2015 to 2023.
  • Adaptimmune Therapeutics PLC Net Cash Provided by (Used in) Investing Activities for the quarter ending March 31, 2024 was -$358K, a 101% decline year-over-year.
  • Adaptimmune Therapeutics PLC annual Net Cash Provided by (Used in) Investing Activities for 2023 was $177M, a 98.1% increase from 2022.
  • Adaptimmune Therapeutics PLC annual Net Cash Provided by (Used in) Investing Activities for 2022 was $89.1M, a 17.6% increase from 2021.
  • Adaptimmune Therapeutics PLC annual Net Cash Provided by (Used in) Investing Activities for 2021 was $75.8M.
Net Cash Provided by (Used in) Investing Activities, Annual (USD)
Net Cash Provided by (Used in) Investing Activities, YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 $177M +$87.4M +98.1% Jan 1, 2023 Dec 31, 2023 10-K 2024-03-06
2022 $89.1M +$13.3M +17.6% Jan 1, 2022 Dec 31, 2022 10-K 2024-03-06
2021 $75.8M +$355M Jan 1, 2021 Dec 31, 2021 10-K 2024-03-06
2020 -$279M -$374M -394% Jan 1, 2020 Dec 31, 2020 10-K 2023-03-06
2019 $94.9M +$112M Jan 1, 2019 Dec 31, 2019 10-K 2022-03-14
2018 -$17.5M +$109M +86.2% Jan 1, 2018 Dec 31, 2018 10-K 2021-02-25
2017 -$126M -$144M -810% Jan 1, 2017 Dec 31, 2017 10-K 2019-02-27
2016 $17.8M +$76.6M Jan 1, 2016 Dec 31, 2016 10-K 2019-02-27
2015 -$58.8M Jul 1, 2014 Jun 30, 2015 10-K 2018-03-15
* An asterisk sign (*) next to the value indicates that the value is likely invalid.